Ocuphire Pharma (OCUP) Stock Highlights

1.33 | +1.53%

2024-09-19 06:47:04

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphires pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Statistics

Range Today

1.32 1.37

Volume Today 89.4K

Range 1 Year

1.15 4.5

Volume 1 Year 52.18M

Range 3 Year

1.15 6.6

Volume 3 Year 252.3M

Range 10 Year

1.15 460.8

Volume 10 Year 416.64M

Highlights

Market Capitalization 34.06M (micro)

Floating Shares 24.52M

Current Price 1.33

Price To Earnings -2.35

Price To Revenue -0.51

Price To Book 0.83

Earnings Per Share -0.54

Payout Ratio 0%

Performance

Latest +1.53%

1 Month +0.76%

3 Months -20.83%

6 Months -29.26%

1 Year -66.83%

3 Years -73.45%

5 Years -85.61%

10 Years -99.65%

Benchmarks

Market Capitalization

284 / 368

Gross Profits

0 / 278

Total Revenue

114 / 300

Total Rank

11 / 368

Free Cashflow

29 / 352

Performance 5 years

270 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.